|
| Topic | Findings | Reference |
|
| Preclinical and clinical data on AD review | 1477 studies published until November 2020 were considered and 24 met the inclusion criteria for the review. Only 4 studies indicated that the effects of saffron on cognitive impairment were not different from those produced by donepezil and memantine and that it had a better safety profile. So further studies are needed to establish the possible role of saffron in AD | [24] |
| Mild to moderate depression clinical | Saffron was effective for treating mild to moderate depression and had comparable efficacy to synthetic antidepressants | [25] |
| Multiple sclerosis review | Saffron may prove beneficial in improving antioxidant defense and oxidative stress in patients with MS; however, the evidence appears scattered, heterogeneous, and inadequate, so trials of better design and MS-specific outcomes are required | [26] |
| Adults with poor sleep, sleep quality, cortisol, and melatonin concentrations | Supplementation with standardized extract (Affron®) 14 mg or 28 mg. The authors reported sleep-enhancing effects of 28 days with saffron supplementation in adults | [27] |
| C. sativus for insomnia | Although there is limited evidence of a very low to moderate quality, C. sativus may benefit people with insomnia | [28] |
| Adjunctive therapy in adults with attention-deficit/hyperactivity disorder | Saffron combination therapy with Ritalin can effectively improve symptoms of patients with ADHD | [29] |
| Management of premenstrual dysphoric disorder | 15 mg of saffron for 2 weeks in the luteal phase of two menstruation cycles. Treatment was an efficacious herbal agent for the treatment of PMDDwith minimal adverse effects | [30] |
| Insomnia | Intranasal formulation containing oily macerates of Viola odorata L., Crocus sativus L., and Lactuca sativa L. 0.02 mg/mL crocin and 4 μg/mL isoquercitrin | [31] |
|
